Advanced searches left 3/3

Car-t Cells Leukemia - Europe PMC

Summarized by Plex Scholar
Last Updated: 09 August 2022

* If you want to update the article please login/register

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia.

The prognosis for acute or refractory acute myeloid leukemia is poor. We evaluated chimeric antigen receptor T cell therapy in adults with CLL-1 disease in adults with R/R AML patients in this research. Patients were treated with cyclophosphamide and fludarabine for three days, as well as an infusion of a dose of 1-2 u00d7 10 6 CAR-T cells/kg. No patient suffered with CAR-T cell-related encephalopathy syndrome. The complete response /CR with a poor hematologic recovery rate was 70%. In less than two weeks, CAR-T cells demonstrated peak expansion within 2 weeks. Notably, CLL-1 is also highly expressed in normal granulocytes, so stem cell transplantation may be a viable option to restore long-term agranulocytosis due to off-target toxicity. In conclusion, this is the first to demonstrate the efficacy and tolerable safety of CLL-1 CAR-T cell therapy in adult R/R AML.

Source link: https://europepmc.org/article/MED/35799191

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions